• CPhI: Drugs pipeline is discouraging and slowing simple manufacturing innovations

    CPhI Worldwide report states the current drugs pipeline is discouraging and slowing simple manufacturing innovations. This was announced in its fifth edition of the CPhI Annual Report, which focuses on the immediate and long-term trends in pharmaceutical manufacturing and ingredients.

  • AstraZeneca and Merck said Wednesday that th eUS Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in metastatic breast cancer.

  • Silence gets more US patnets

    Silence Therapeutics got the US Patent and Trade Mark Office on Tuesday, after previously reporting issuance of a notice of allowance for US patent application on August 15, 2017 and for US patent application on September 11, 2017.

  • Novartis with positive results for Revolade for chronic/persistent immune thrombocytopenia (ITP) The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland October 22, 2013. REUTERS/Arnd Wiegmann/File Photo

    Novartis on Wednesday announced long-term study results supporting the positive safety and efficacy of Revolade in adults with chronic immune (idiopathic) thrombocytopenia (ITP) were published online in Blood.

  • Fortune: Horizon Pharma one of the Best Small & Medium Workplaces in 2017 Horizon Pharma logo

    Horizon Pharma has been named one of the 2017 Best Small & Medium Workplaces by FORTUNE and Great Place to Work for the second year in a row. 

  • Gilead Sciences names Alessandro Riva to Executive Vice President, Oncology Therapeutics Gilead Sciences

    Gilead Sciences has promoted Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell therapy research and development. Dr. Riva will become a member of Gilead’s senior leadership team.

  • FDA accepts supplemental BLA for AZ’s Imfinzi in certain lung cancer AstraZeneca

    The US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for AstraZeneca’s Imfinzi (durvalumab) for the treatment of patients with locally advanced (Stage III) unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy. The FDA has granted Imfinzi Priority Review status.

  • Frank Staud assumes overall responsibility for the STADA brand and communications The logo of the pharmaceutical company Stada Arzneimittel AG is pictured at its headquarters in Bad Vilbel near Frankfurt March 14, 2012. REUTERS/Alex Domanski

    Frank Staud assumed the role of Executive Vice President Corporate Communications, Branding and Sponsoring on October 1. The 48-year old Austrian is responsible not only for the image of the STADA brand, but also for all of the Group’s communication activities. These include corporate and product communication, change communication as

  • Plasticell, GSK ink deal to produce hematopoietic cells from iPSCs gsk

    Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its

  • The US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the Novo Nordisk’s  New Drug Application (NDA) for approval of semaglutide,  for the treatment of type 2 diabetes in adults.